POWER (Pulse Width Optimized Waveform Evaluation Trial)

Completed · Phase 4

Conditions studied: Sudden Cardiac Death

In brief

The objective of this study is to compare the ULV (Upper Limit of Vulnerability)/DFT (Defibrillation Threshold) efficacy between the 2.5, 3.5 and 4.5 ms membrane time constant based biphasic defibrillation waveforms. This comparison will result in identifying the optimal membrane time constant when programming the "tuned" defibrillation waveform.

Key facts

Study ID

NCT00311181

Run by

Abbott Medical Devices

People needed

217

Starts

2006-08-01

Expected to finish

2008-04-01

Last updated by the study team

2019-02-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient is a candidate for ICD/CRT-D implantation.
• Patient has a compatible transvenous defibrillation lead system.
• Patient has had an echocardiogram, MUGA, or cath procedure within 6 months of ICD/CRT-D implant.
• Patient is able to tolerate ULV guided DFT testing.

You may not qualify if…

• Patient has a mechanical valve in the tricuspid position.
• Patient has epicardial defibrillation electrodes.
• Patient is pregnant.
• Patient is less than 18 years old.

Where it is running

• Baptist Medical Center Montclair — Birmingham, Alabama, United States
• Pacific Heart Institute — Santa Monica, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.